Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin Safety Extension in Parkinson's Disease Psychosis
NCT01518309Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2004
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimavanserin in Parkinson's disease (PD), sponsored by Acadia Pharmaceuticals. Started Nov 2004; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01518309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01518309.